Soluble HLA-G blood levels are not increased during ongoing pregnancy in women with a history of recurrent pregnancy loss.

BMI HLA-G polymorphisms RPL with subsequent ongoing pregnancy Recurrent Pregnancy Loss Soluble HLA-G

Journal

Journal of reproductive immunology
ISSN: 1872-7603
Titre abrégé: J Reprod Immunol
Pays: Ireland
ID NLM: 8001906

Informations de publication

Date de publication:
09 2022
Historique:
received: 13 01 2022
revised: 30 05 2022
accepted: 11 07 2022
pubmed: 30 7 2022
medline: 20 9 2022
entrez: 29 7 2022
Statut: ppublish

Résumé

Recurrent pregnancy loss (RPL) affects 1-2 % of couples who are trying to conceive. At some point, some couples do maintain a healthy pregnancy to term, but the underlying mechanism of RPL remains elusive. Human leukocyte antigen (HLA)-G is an immune modulatory molecule. Our group previously showed increased HLA-G levels in the decidua of term pregnancies after RPL, while other studies showed reduced soluble HLA-G (sHLA-G) blood levels in women with RPL. This led us to investigate sHLA-G levels in blood of women with RPL who had either a subsequent pregnancy loss (RPL-pregnancy loss) or a healthy term pregnancy (RPL-live birth), and compare these to healthy control pregnancies and non-pregnant controls. Soluble HLA-G concentrations were quantified by ELISA. Women with healthy term pregnancy had increased sHLA-G levels compared to non-pregnant controls. In contrast, RPL-live birth women at term did not have increased blood sHLA-G levels. Soluble HLA-G levels remained stable between first and third trimester. Interestingly, when comparing first trimester samples of RPL-live birth to RPL-pregnancy loss, sHLA-G levels also did not significantly differ. High sHLA-G levels in blood seem not to be crucial for an ongoing healthy pregnancy after RPL. However, since it was previously shown that women with RPL-live birth have increased HLA-G levels in term decidua compared to control pregnancies, the current data suggest that local and systemic immune regulation are not necessarily in concert. Further study of the contribution of fetus-derived HLA-G and HLA-G of maternal origin may provide more insight in the pathophysiology of RPL.

Identifiants

pubmed: 35905658
pii: S0165-0378(22)00194-2
doi: 10.1016/j.jri.2022.103665
pii:
doi:

Substances chimiques

HLA-G Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103665

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

J Krop (J)

Department of Immunology, Leiden University Medical Centre, Leiden, the Netherlands.

C Van Der Keur (C)

Department of Immunology, Leiden University Medical Centre, Leiden, the Netherlands.

J M Kapsenberg (JM)

Department of Immunology, Leiden University Medical Centre, Leiden, the Netherlands.

F Den Hollander (F)

Department of Immunology, Leiden University Medical Centre, Leiden, the Netherlands.

M L P Van Der Hoorn (MLP)

Department of Obstetrics, Leiden University Medical Centre, Leiden, the Netherlands.

S Heidt (S)

Department of Immunology, Leiden University Medical Centre, Leiden, the Netherlands.

F H J Claas (FHJ)

Department of Immunology, Leiden University Medical Centre, Leiden, the Netherlands.

M Eikmans (M)

Department of Immunology, Leiden University Medical Centre, Leiden, the Netherlands. Electronic address: m.eikmans@lumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH